We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viropharma Incorporated (MM) | NASDAQ:VPHM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.98 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
LONDON--Shire PLC (SHP.LN) is buying rare disease company ViroPharma Inc. (VPHM) for $4.2 billion, or $50 a share, a deal that would enhance its short- and long-term revenue growth profile, the U.K. specialty biopharmaceutical company said Monday.
The purchase price is a 27% premium to ViroPharma's closing share price Friday.
Shire said it expects annual cost synergies of $150 million by 2015, over and above the improved operating leverage already being driven by the company's ongoing "One Shire" reorganization. The deal is expected to be immediately accretive to Shire's non-GAAP earnings per share after completion and to enhance its earnings growth profile, it said.
The acquisition to be affected by a tender offer and funded from Shire's cash resources as well as existing and new bank facilities.
Shire shares closed in London Friday at 2796 pence, valuing the company at 15.49 billion pounds ($24.9 billion).
-Write to Ian Walker at ian.walker@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Viropharma Incorporated (MM) Chart |
1 Month Viropharma Incorporated (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
